Male Reproductive, Prostate Cancers | Resource & Information Center

Male Reproductive Cancers

Prior Sunitinib Treatment May Prolong Progression-Free Survival with Subsequent TKI Use

First-line treatment with sunitinib for 9 months or more may be associated with a longer progression-free survival (PFS) in patients who receive subsequent VEGFR tyrosine kinase inhibitors, results of Phase 3 AXIS trial data in second-line metastatic renal cell carcinoma (RCC) comparing axitinib and sorafenib presented during the 2012 Genitourinary Cancers Symposium have found.